Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
NCT03107026Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dasotraline in binge eating disorder (BED) (3 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Change From Baseline in Number of Binge Days at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
dasotraline
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT03107026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107026.